Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New cocktail of drugs shows promise for tough lung cancer

NCT ID NCT03819465

Disease control Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage trial tests whether combining the immunotherapy durvalumab with other experimental drugs (danvatirsen, oleclumab) and/or chemotherapy can safely control stage IV non-small cell lung cancer. About 175 people who have not had prior treatment for metastatic disease will receive different drug combinations. The main goal is to check safety and see if tumors shrink.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
durvalumab (an immunotherapy) combined with danvatirsen, oleclumab, and/or chemotherapy
What this could lead to
If successful, this could point toward new combination treatments that help control advanced lung cancer for longer.
What could go wrong
This is a very early (Phase 1) trial with only 175 participants, so results may not apply broadly. Side effects from combining multiple drugs are unknown.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1

The first testing in people. Mainly checks safety and dose, usually in a small group.

Participants

175 people

The number who actually took part.

Started

Dec 2018

Expected to finish

Jul 2026

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 130 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Histologically or cytologically documented Stage IV NSCLC not amenable to curative surgery or radiation * No prior chemotherapy or any other systemic therapy for metastatic NSCLC * Prior platinum-containing adjuvant, neoadjuvant, or definitive chemoradiation for advanced disease are eligible, if progression has occurred \>12 months from end of last therapy * Known tumor PD-L1 status * Tumors that lack activating EGFR mutations and ALK fusions or documented local test result for any other known genomic alteration for which a targeted therapy is approved in first line per local standard of care * WHO/ECOG status at 0 or 1 at enrollment * Life expectancy of at least 12 weeks * Troponin I or T ≤ ULN (per institutional guidelines) Exclusion Criteria: * Active or prior documented autoimmune or inflammatory disorders * History of active primary immunodeficiency * Any prior chemotherapy or any other systemic therapy for metastatic NSCLC * Untreated CNS metastases

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Metastatic non-small cell lung cancer (NSCLC) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Metastatic non-small cell lung cancer (NSCLC)

Contacts and locations

Locations

  • Research Site

    Iowa City, Iowa, 52242, United States

  • Research Site

    Pittsburgh, Pennsylvania, 15212, United States

  • Research Site

    Nashville, Tennessee, 37203, United States

  • Research Site

    Salzburg, 5020, Austria

  • Research Site

    Vienna, 1140, Austria

  • Research Site

    Edegem, 2650, Belgium

  • Research Site

    Bialystok, 15-027, Poland

  • Research Site

    Bydgoszcz, 85-796, Poland

  • Research Site

    Gdansk, 80-214, Poland

  • Research Site

    Grudziądz, 86-300, Poland

  • Research Site

    Lodz, 90-302, Poland

  • Research Site

    Olsztyn, 10-357, Poland

  • Research Site

    Tomaszów Mazowiecki, 97-200, Poland

  • Research Site

    Warsaw, 02-781, Poland

  • Research Site

    Wroclaw, 53-413, Poland

  • Research Site

    Krasnoyarsk, 660133, Russia

  • Research Site

    Moscow, 115478, Russia

  • Research Site

    Saint Petersburg, 191014, Russia

  • Research Site

    Saint Petersburg, 197758, Russia

  • Research Site

    Cheongju-si, 28644, South Korea

  • Research Site

    Seoul, 03722, South Korea

  • Research Site

    Seoul, 05505, South Korea

  • Research Site

    Seoul, 06351, South Korea

  • Research Site

    Seoul, 110-744, South Korea

  • Research Site

    Barcelona, 08025, Spain

  • Research Site

    Barcelona, 8003, Spain

  • Research Site

    Madrid, 28034, Spain

  • Research Site

    Madrid, 28041, Spain

  • Research Site

    Seville, 41013, Spain

  • Research Site

    Kaohsiung City, 807, Taiwan

  • Research Site

    Taichung, 402, Taiwan

  • Research Site

    Taichung, 40705, Taiwan

  • Research Site

    Tainan, 70403, Taiwan

  • Research Site

    Taipei, 10002, Taiwan

  • Research Site

    Taipei, 112, Taiwan

  • Research Site

    Taipei, 235, Taiwan

  • Research Site

    Taoyuan, 333, Taiwan

  • Research Site

    Bangkok, 10330, Thailand

  • Research Site

    Bangkok, 10700, Thailand

  • Research Site

    Chiang Mai, 50200, Thailand

  • Research Site

    Hat Yai, 90110, Thailand

More trials for these conditions

Other studies related to the condition(s) this trial covers.